Abivax Shares Continue Correction at Close with a Decline of 3.42%
French biotech Abivax closed down 3.42% this Thursday, December 4, at 93.30 euros, compared to 96.60 euros the previous day. Another session of consolidation in a context of profit-taking after a spectacular surge of 1,118% over a year, making it the top performer of the Stoxx 600 in 2025. Trading volume remained limited to 0.14% of the capital, in a Parisian market up by 0.43%.
Continued Short-Term Consolidation for Abivax
After a decline of 4.92% the previous day to close at 96.60 euros, Abivax continues its short-term consolidation movement. Over a week, the decline amounts to 16.55%, marking a correction phase after a remarkable surge of 40% over three months, which still brings the quarterly performance to 30.49%. This volatility is part of a broader reevaluation of the stock, which has jumped by more than 1,100% since the beginning of the year, propelled by positive Phase 3 trial results of ABTECT on Obefazimod in the treatment of ulcerative colitis. Abivax's market capitalization now exceeds 8 billion dollars, making the company one of the most highly valued French biotechs in Paris. Investors are digesting the meteoric rise of the stock since July 2025, when the first encouraging clinical results were unveiled. Abivax still has to present the results of the 44-week maintenance study, expected in the second quarter of 2026, before it can file for marketing authorization with the FDA and EMA.
Technical Perspective on Abivax's Stock
Technically, the stock is currently trading above its 50-day moving average, which stands at 87.08 euros, indicating a still constructive medium-term dynamic despite the recent decline. The current price of 93.30 euros is positioned between the identified support at 79.20 euros and major resistance at 111.80 euros. The RSI indicator at 57 points suggests a still positive momentum, with no signs of overbuying, leaving room for a potential rebound. The MACD shows a slight reversal signal with a MACD line at 4.88 crossing below the signal line at 5.63, and a negative histogram at -0.74, indicating a short-term loss of momentum and justifying investor caution. The 200-day moving average, positioned at 40.01 euros, illustrates the radical transformation of the stock's trajectory in 2025. The considerable gap between the current price and this average reflects the magnitude of the revaluation undertaken this year. The one-month volatility reaches 17.56%, reflecting significant fluctuations characteristic of biotechnology stocks in advanced clinical trial phases. The negative beta of -0.38 suggests a relative decorrelation with the CAC 40 index, which has progressed by 11.94% over the year.
